Significance of endogenous augmentation of antiganglioside IgM in cancer patients: Potential tool for early detection and management of cancer therapy

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 212-222

  Ravindranath, Mepur H ^a   Muthugounder, Sakunthala ^a   Hannah, Maghasi R ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Antiganglioside IgM antibody; Ascitic fluid; Colon cancer; Melanoma; Ovarian epithelial cancer; Plasma; Prostate cancer; Sarcoma; Serum; Total gangliosides

Indexed keywords

GANGLIOSIDE; IMMUNOGLOBULIN M; TUMOR MARKER;

ANTIBODY RESPONSE; CANCER PATIENT; CANCER THERAPY; CONFERENCE PAPER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MELANOMA; MICROENVIRONMENT; OVARY CANCER; PROSTATE CANCER; SOFT TISSUE SARCOMA; ARTICLE; BLOOD; FEMALE; IMMUNOLOGY; MALE; NEOPLASM; TIME;

FEMALE; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN M; MALE; NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34648843896     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.023     Document Type: Conference Paper

References (22)

1. HAKANSSON, L., P. FREDMAN & L. SVENNERHOLM. 1985. Gangliosides in serum immune complexes from tumor-bearing patients. J. Biochem. 98: 843-849.
2. TONEGAWA, Y. & S-I. HAKOMORI. 1977. "Ganglioprotein and globoprotein": the glycoproteins reacting with anti-ganglioside and anti-globoside antibodies and the ganglioprotein change associated with transformation. Biochem. Biophys. Res. Commun. 76: 9-17.
3. VALENTINO, L.A. & S. LADISCH. 1992. Localization of shed human tumor gangliosides: association with lipoproteins. Cancer Res. 52: 810-814.
4. KONG, Y., R. LI & S. LADISCH. 1998. Natural forms of shed tumor gangliosides. Biochim. Biophys. Acta 1394: 43-56.
5. DOLO, V., R. LI, M. DILLINGER, et al. 2000. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochem. Biophys. Acta 1486: 265-274.
6. KALASHNIKOVA, M.M. 1985. Appearance of clasmatosis in the normal and pathological liver. Bull. Eksp. Biol. Med. 100: 355-358.
7. KERYER-BIBENS, C., C. PIOCHE-DURIEU, C. VILLEMANT, et al. 2006. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 8: 283.
8. MORRIS, V.L., I.C. MACDONALD, S. KOOP, et al. 1993. Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: video-microscopic analysis. Clin. Exp. Metastasis 11: 377-390.
9. KELLER, S., M.P. SANDERSON, A. STOECK, et al. 2006. Exosomes: from biogenesis and secretion to biological function. Immunol. Lett. 107: 102-106.
10. RAVINDRANATH, M.H., D.L. MORTON & R.F. IRIE. 1994. Attachment of monophosphoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides. J. Autoimmun. 7: 803-816.
11. BERGELSON, L.D. 1995. Serum gangliosides as endogenous immunomodulators. Immunol. Today 16: 483-486.
12. SHURIN, G.V., M.R. SHURIN, S. BYKOVSKAIA, et al. 2001. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61: 363-369.
13. CHAHLAVI, A., P. RAYMAN, A.L.B. RICHMOND, et al. 2005. Glioblastomas induce T- lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 65: 5428-5438.
14. THORNTON, M.V., D. KUDO, P. RAYMAN, et al. 2004. Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J. Immunol. 172: 3480-3490.
15. PEREZ, C.A., M.H. RAVINDRANATH, D. SOH, et al. 2002. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J. 8: 384-394.
16. RAVINDRANATH, M.H., T.F. WOOD, D. SOH, et al. 2002. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 45: 10-21.
17. RAVINDRANATH, M.H., R.M. RAVINDRANATH, D.L. MORTON, et al. 1994. Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J. Immunol. Methods 169: 257-272.
18. RAVINDRANATH, M.H., S. MUTHUGOUNDER, T.S. SARAVANAN, et al. 2005. Human antiganglioside autoantibodies: validation of ELISA. Ann. N.Y. Acad. Sci. 1050: 229-242.
19. RAVINDRANATH, M.H., E.C. HSUEH, M. VERMA, et al. 2003. Serumtotal ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine. J. Immunother. 26: 277-285.
20. RAVINDRANATH, M.H., S. MUTHUGOUNDER, N. PRESSER, et al. 2005. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int. J. Cancer 116: 368-377.
21. RAVINDRANATH, M.H., A.M. GONZALES, K. NISHIMOTO, et al. 2000. Immunology of gangliosides. Indian J. Exp. Biol. 38: 301-312.
22. RAVINDRANATH, M.H., S. MUTHUGOUNDER, N. PRESSER, et al. 2007. Immunogenicity of gangliosides in ovarian epithelial cancer. Biochem. Biophys. Res. Commun. 353: 251-258.